Uncover the benefits of integrative treatment for managing migraines and promoting overall wellness with chiropractic care.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through a clear, first-person, clinically grounded journey into migraine diagnosis and treatment that is easy to follow yet deeply thorough. I distill modern pathophysiology, outline evidence-based acute and preventive therapeutics, and share practical workflows for primary care, neuromusculoskeletal providers, and multidisciplinary clinics. You will learn how to differentiate migraine from other primary and secondary headaches quickly, apply rapid screening tools, identify red flags, and understand why timing and mechanism matter for treatment selection.

I unpack the neurological and neuroimmune underpinnings of migraine — including hypothalamic dysmodulation, trigeminovascular activation, neuropeptides like Calcitonin Gene-Related Peptide (CGRP), and serotonin (5-HT1) receptor pharmacology — and I show how these insights translate into real-world decisions for triptans, ditans, gepants, CGRP monoclonal antibodies, onabotulinumtoxinA, neuromodulation, and integrative strategies across sleep, nutrition, stress, and rehabilitative care.

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, I practice integrative chiropractic and functional medicine with medical direction from Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933), our Medical Director and Collaborative Physician, who has over 40 years of experience in internal medicine. Together, we co-manage complex headache and pain presentations through a multidisciplinary lens that blends medical oversight, diagnostics, pharmacology, procedural options, chiropractic care, soft-tissue and joint-focused rehabilitation, neuro-orthopedic assessment, functional medicine, and personal injury case management.

This post presents implementation-ready protocols, clinical algorithms, nuanced decision-making guidance, physiologic rationales for each intervention, and detailed narratives reflecting my observations from practice and professional postings at Chiropracticscientist.com and LinkedIn. I include APA-7 style citations, hyperlink key references, and highlight essential terms to make this a practical resource for clinicians and patients.

Keywords: migraine, headache, CGRP, triptan, ditan, gepant, neuromodulation, functional medicine, integrative chiropractic, hypothalamus, trigeminovascular, personal injury, rehabilitation, autonomic dysfunction, photophobia, phonophobia, vestibular migraine, cervicogenic headache

About Our Multidisciplinary Care Model In El Paso, Texas

I am Dr. Alex Jimenez, and I serve patients with neuromusculoskeletal, metabolic, and injury-related conditions at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. Our integrative framework is anchored by the medical leadership of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine), our Medical Director and Collaborative Physician. Dr. Cardenas brings over 40 years of internal medicine experience and oversees medical safety, diagnostics, pharmacotherapy, and coordination with specialists when needed (NPI #1164426749; Texas MD License #J2933).

Our multidisciplinary model is typical for modern integrative and injury care clinics and includes:

• I provide direct integrative chiropractic care, regional biomechanics, joint and soft tissue management, and functional rehabilitation.
• Cardenas oversees medical diagnostics and pharmacologic therapy, including acute and preventive migraine treatments, and assesses comorbidities (hypertension, dyslipidemia, metabolic syndrome, autoimmune conditions).
• We integrate functional medicine — nutritional biochemistry, sleep optimization, stress regulation, and lifestyle therapeutics — with evidence-based manual therapy, targeted exercise, vestibular and oculomotor rehabilitation, and ergonomic interventions.
• For personal injury cases, we document mechanism of injury, functional impairments, and serial outcomes, and coordinate with legal and occupational stakeholders when appropriate.

This collaborative structure allows us to address the neurovascular biology of migraine, cervicothoracic contributors, autonomic dysregulation, and whole-person factors such as sleep, hormones, and metabolic health in a unified plan.

Why This Educational Post Matters

• Primary care clinicians manage most migraine. Up to 70% of people with migraine are cared for outside specialty neurology. I designed this post to empower front-line providers with succinct tools, differential diagnoses, and implementation-ready protocols (Goadsby et al., 2017; Ailani et al., 2021).
• Migraine is common and disabling. More than a billion people live with migraine worldwide. One in five women and one in sixteen men are affected; roughly one in eleven children experience migraine (Steiner et al., 2018).
• Treatments are evolving rapidly. New classes — CGRP monoclonal antibodies, small-molecule CGRP antagonists (gepants), and 5-HT1F agonists (ditans) — expand options for patients who cannot tolerate or do not respond to triptans (Ailani et al., 2021).
• Integrative care improves outcomes. Combining internal medicine oversight with chiropractic care, functional medicine, and rehabilitation supports better diagnosis, safer pharmacologic plans, targeted manual therapy, exercise, and metabolic optimization—especially post-injury.

How I Reframe Migraine: A Whole-Person, Systems Approach

I understand migraine as a dynamic neurovascular and neuroimmune disorder featuring central dysmodulation, trigeminovascular activation, and sensitization in both peripheral and central networks (Goadsby et al., 2017; Charles, 2018; Edvinsson, 2019). Each patient’s migraine signature may include:

• Hypothalamic premonitory changes
• Aura in ~30% (visual, sensory, language, or brainstem features)
• Throbbing or movement-aggravated head pain (often unilateral, but bilateral and pressure-like is common)
• Autonomic symptoms: nausea, vomiting, photophobia, phonophobia, osmophobia
• Neck stiffness and myofascial tenderness as prodrome or perpetuating influences
• Postdromal fatigue, cognitive fog, and allodynia

Our blended care plans address:

• Neural excitability and sensory processing
• Meningeal neuropeptide signaling (especially CGRP)
• Serotonergic modulation of trigeminovascular pathways (5-HT1 receptors)
• Myofascial drivers including upper cervical mechanics and thoracic inlet dynamics
• Sleep, nutrition, glycemic stability, hydration, and micronutrient sufficiency
• Autonomic balance (sympathetic/parasympathetic regulation)
• Psychophysiological stress and behavioral triggers
• Injury-related exacerbations and cervicogenic overlaps

Epidemiology: The Scope And Implications

• Over 1 billion people worldwide are affected, with a significant female predominance (Steiner et al., 2018).
• One in four U.S. households includes someone with migraine (Goadsby et al., 2017).
• Pediatric prevalence is ~1 in 11 children; pre-menarchal rates are similar in girls and boys (Ashina et al., 2021).
• Most individuals are managed in primary care — emphasizing the need for rapid, accurate diagnosis and first-line management.

Clinical implication: Think migraine first when the phenotype suggests movement-aggravated, moderate-to-severe head pain with sensory sensitivities — even when bilateral or pressure-like. Avoid anchoring bias: adolescents, peri-menopausal women, post-concussive patients, and older men can all present with migraine patterns (Goadsby et al., 2017).

References:

• The pathophysiology of migraine: Implications for clinical management (Goadsby et al., 2017)
• The global burden of headache (Steiner et al., 2018)

Differentiating Primary From Secondary Headache: The SNOOP10 Red Flags

I begin every headache evaluation by excluding secondary causes through SNOOP/SNOOP10 red flags (Dodick, 2003; AHS Guidelines):

Core SNOOP:

• S: Systemic symptoms or secondary risk factors (fever, weight loss, myalgias; cancer, HIV, pregnancy)
• N: Neurologic deficits (focal deficits, confusion, seizures, papilledema)
• O: Onset sudden/thunderclap (risk of subarachnoid hemorrhage)
• O: Older age at onset (>50 years)
• P: Pattern change or precipitated by Valsalva, posture, exertion, sexual activity; progressive course

Additional risk clues:

• New daily persistent headache
• Positional headache (CSF pressure disorders)
• Jaw claudication (giant cell arteritis)
• Post-traumatic changes, anticoagulation, immunosuppression

Immediate actions when red flags are present:

• Urgent neuroimaging (non-contrast CT for thunderclap; MRI/MRA/MRV as indicated)
• Lumbar puncture if SAH suspected but CT negative within 6 hours
• ESR/CRP and temporal artery assessment for suspected giant cell arteritis
• ED or neurology triage depending on presentation

Clinical rationale: These features predict higher risk of intracranial pathology where time-sensitive diagnostics change outcomes (Dodick, 2003).

References:

• SNOOP: systemic symptoms, neurologic signs, sudden onset, onset after age 50, and pattern change (Dodick, 2003)
• American Headache Society guidelines

Migraine Versus Tension-Type Headache: Practical Differentiation

A common pitfall is misclassifying migraine as tension-type headache (TTH) (ICHD-3; Ashina et al., 2021). I use these distinctions:

• Duration

• • Migraine: 4–72 hours (2–72 hours in children)
  • TTH: 30 minutes to 7 days

• Location

• • Migraine: unilateral or bilateral (~40% bilateral)
  • TTH: typically bilateral

• Quality

• • Migraine: throbbing/pulsating common, can be pressure-like
  • TTH: pressing/tightening, non-pulsating

• Intensity

• • Migraine: moderate to severe
  • TTH: mild to moderate

• Associated symptoms

• • Migraine: photophobia/phonophobia, nausea/vomiting
  • TTH: at most one of photophobia or phonophobia; minimal nausea, no vomiting

• Aggravation by activity

• • Migraine: worse with routine physical activity (standing, walking stairs)
  • TTH: not aggravated by routine activity

High-yield question: “Does routine activity make your headache worse?” If yes, think migraine (ICHD-3).

References:

• The International Classification of Headache Disorders, 3rd edition
• Migraine: epidemiology and systems of care (Ashina et al., 2021)

Rapid Migraine Screening In Primary Care: The ID Migraine Tool

For quick screening, I rely on ID Migraine (PIN) — a validated three-item tool (Lipton et al., 2003):

• P: Photophobia — Does light bother you during headaches?
• I: Impairment — Have headaches limited activities for at least one day in the last three months?
• N: Nausea — Do you feel sick to your stomach during headaches?

Two “yes” answers predict migraine with high probability when focal neurological findings are absent. It is fast, practical, and increases diagnostic accuracy.

Reference:

• Validation of a brief migraine screener in primary care (Lipton et al., 2003)

The Migraine Attack Continuum: Phases And Clinical Clues

I assess the entire attack continuum, not just head pain (Giffin et al., 2003; Goadsby et al., 2017):

• Interictal: Symptom-free interval; track frequency and treatment response.
• Prodrome (premonitory): Up to 70% have early signs hours to a day before pain — light and sound sensitivity, yawning, neck stiffness, cognitive fog, food cravings, mood changes, dizziness/vertigo.
• Aura (~30%): Transient, fully reversible neurological symptoms over 5–60 minutes. Most commonly visual positive phenomena (fortification spectra, scintillations) radiating outward. Sensory, language, and brainstem auras occur.
• Headache phase: 4–72 hours of throbbing/pulsating pain aggravated by movement with photophobia/phonophobia, nausea/vomiting; cervical myofascial tenderness is common.
• Postdrome: Up to 24 hours of fatigue, cognitive slowing, scalp tenderness, and allodynia.

Practical takeaway: Recognizing prodrome and aura enables preemptive treatment and trigger mitigation.

References:

• Premonitory symptoms in migraine (Giffin et al., 2003)
• Pathophysiology of migraine (Goadsby et al., 2017)

Pathophysiology: Central Dysmodulation And Trigeminovascular Activation

I organize pathophysiology into central and peripheral processes (Goadsby et al., 2017; Charles, 2018; Edvinsson, 2019):

• Central dysmodulation:

• • Hypothalamus: Imaging shows activation preceding attacks; aligns with prodrome and autonomic/behavioral shifts.
  • Thalamic sensory gating: Alters sensory processing, promoting photophobia and phonophobia.
  • Brainstem nuclei (dorsal pons, PAG): Modulate nociception and descending inhibition.
  • Cortical spreading depolarization (CSD): Transient neuronal-glial depolarization linked to aura; triggers meningeal nociception and neurogenic inflammation.

• Trigeminovascular system:

• • Activation of trigeminal afferents innervating meningeal vessels and dura leads to release of CGRP and other peptides.
  • CGRP effects: potent vasodilator, mast cell activator, sensitizes peripheral and central nociceptive neurons; sustains pain via neurogenic inflammation.
  • Serotonin pathways: 5-HT1B/1D/1F activation inhibits trigeminal neurotransmission — the basis for triptans and ditans.

• Sensitization:

• • Peripheral sensitization of meningeal nociceptors increases pain with movement and vascular pulsation.
  • Central sensitization manifests as allodynia and persistent postdrome; it is linked to heightened brainstem excitability.

Clinical implications:

• CGRP-targeted therapies and 5-HT1 agonists fit the mechanistic model.
• Treat early to limit peripheral and central sensitization.
• Lifestyle and functional medicine target autonomic/metabolic prodromes.

References:

• CGRP and migraine (Edvinsson, 2019)
• Migraine (Charles, 2018)
• Pathophysiology overview (Goadsby et al., 2017)

Integrating Chiropractic Care Into Migraine Management

As a chiropractic physician and nurse practitioner, I blend manual and rehabilitative strategies with medical and functional care, targeting musculoskeletal contributors, autonomic tone, and movement-related aggravators (Biondi, 2005; Luedtke et al., 2012):

Clinical observations from my practice and postings (Chiropracticscientist.com; LinkedIn):

• Upper cervical segmental dysfunction (C0–C3) and myofascial trigger points in suboccipitals, SCM, upper trapezius, and temporalis can amplify trigeminocervical complex input, increasing headache intensity and frequency.
• Thoracic hypomobility and altered scapulothoracic mechanics maintain cervicogenic and tension components co-occurring with migraine.
• Forward head posture and prolonged screen use increase pericranial muscle tenderness, shortening attack thresholds in susceptible patients.
• Gentle, precise cervical mobilization/manipulation, soft-tissue release, and sensorimotor control training reduce pericranial sensitivity and improve activity tolerance—especially when paired with medical therapies and sleep optimization.

How chiropractic fits with medical oversight:

• Cardenas ensures safety in patients with vascular risk, osteoporosis, connective tissue disease, anticoagulation, or complex medication regimens.
• We coordinate timing of manual care with pharmacologic plans (e.g., scheduling soft-tissue decompression and vestibular rehab on lower-symptom days; using non-provocative techniques during prodrome).
• We monitor red flags, adjust technique selection for instability or vascular concerns, and co-manage imaging.

References:

• Manual therapies for headache (Biondi, 2005)
• Exercise and physical therapy in migraine (Luedtke et al., 2012)
• ICHD-3

Standard Of Care: Acute Migraine Treatment

My acute strategy is stepwise and mechanism-based (Ailani et al., 2021; Dodick, 2018):

• Non-specific analgesics:

• • NSAIDs (ibuprofen, naproxen, diclofenac) and acetaminophen are first-line for many mild-to-moderate attacks.
  • Rationale: prostaglandin inhibition and reduced neurogenic inflammation; early treatment at onset is best.
  • Caution: Medication overuse headache (MOH) risk with frequent use (?15 days/month for simple analgesics).

• Triptans (5-HT1B/1D agonists):

• • Agents: sumatriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, naratriptan, almotriptan.
  • Mechanism: presynaptic inhibition of trigeminal neurotransmission; cranial vasoconstriction via 5-HT1B; reduces CGRP release.
  • Benefits: high efficacy when taken early; multiple formulations (oral, intranasal, subcutaneous).
  • Contraindications: cardiovascular/cerebrovascular disease, uncontrolled hypertension, hemiplegic/basilar migraine.
  • Interactions: caution with SSRIs/SNRIs (serotonin syndrome rare but monitor).

• Gepants (acute CGRP receptor antagonists):

• • Agents: ubrogepant, rimegepant, zavegepant (intranasal).
  • Mechanism: block CGRP receptor signaling without vasoconstriction.
  • Indications: triptan-intolerant or contraindicated; lower MOH risk; may be effective later in attack.
  • Interactions: CYP3A4 (ubrogepant); assess hepatic impairment.

• Ditans (5-HT1F agonist):

• • Lasmiditan: centrally acting without vasoconstriction; useful when triptans are contraindicated.
  • Note: CNS side effects (dizziness, sedation); do not drive for 8 hours post-dose.

• Antiemetics:

• • Metoclopramide, prochlorperazine, or ondansetron for nausea/vomiting and to facilitate oral absorption.
  • Hydration strategies are essential when vomiting limits oral intake.

• Neuromodulation devices:

• • External vagus nerve stimulation (nVNS), transcutaneous supraorbital stimulation (t-SOS), single-pulse TMS (sTMS), and non-invasive trigeminal/occipital neuromodulation have supportive evidence for selected patients.
  • Rationale: modulate trigeminovascular signaling and cortical excitability without medication interactions.

• Rescue/bridge therapy:

• • For status migrainosus (>72 hours): consider IV hydration, antiemetics, NSAIDs (ketorolac), steroids, or inpatient protocols with medical supervision.

Pragmatic pearls:

• Treat early — ideally in prodrome or pain onset.
• Choose formulation based on symptoms (non-oral routes for severe nausea).
• Avoid MOH through limits: triptans/combination analgesics? 9–10 days/month; simple analgesics: 14–15 days/month.

References:

• AHS Consensus: integrating new migraine treatments (Ailani et al., 2021)
• Contemporary acute treatment review (Dodick, 2018)

Preventive Therapy: Who, When, And How

I recommend preventive therapy when:

• Attacks occur> 4 days/month or cause significant disability even at lower frequencies.
• Acute medications are overused or poorly tolerated.
• Prolonged/complicated auras, vestibular migraine, menstrual migraine, or comorbidities amplify risk.

Options:

• Oral preventives:

• • Beta-blockers (propranolol, metoprolol): reduce neuronal excitability; avoid in asthma/bradycardia.
  • Antiseizure agents (topiramate, valproate): membrane stabilization and GABAergic effects; monitor cognitive effects and teratogenicity (valproate).
  • Tricyclics (amitriptyline, nortriptyline): analgesic/sleep benefits; anticholinergic side effects.
  • SNRIs (venlafaxine): useful with anxiety/depression.
  • Candesartan: antihypertensive with migraine benefit; well-tolerated.

• CGRP monoclonal antibodies (preventive):

• • Agents: erenumab (receptor), fremanezumab, galcanezumab, eptinezumab (ligand binders).
  • Mechanism: blunt CGRP signaling to reduce attack frequency/intensity; long half-lives enable monthly/quarterly dosing.
  • Considerations: constipation and hypertension signals with erenumab; injection-site reactions; low drug-drug interactions.

• Gepants for prevention:

• • Atogepant (daily), rimegepant (every other day): oral CGRP antagonists with flexible dosing and favorable tolerability.

• OnabotulinumtoxinA (Botox) for chronic migraine:

• • Indicated for> 15 headache days/month with> 8 migraine days/month; PREEMPT protocol targets pericranial muscles to modulate nociceptive input (Dodick et al., 2010).

• Neuromodulation (preventive schedules):

• • nVNS, t-SOS, and sTMS can lower monthly migraine days without systemic side effects.

Selection principles:

• Match with comorbidities: beta-blockers for hypertension; SNRIs for mood; topiramate for obesity (weight loss effect); avoid teratogens if pregnancy is possible.
• Consider patient preference for oral vs injectable, onset speed, and tolerability.
• Monitor and adjust every 8–12 weeks; combine with behavioral and rehabilitative care.

References:

• AHS Consensus: preventive therapies (Ailani et al., 2021)
• Pathophysiology and management (Goadsby et al., 2017)
• New therapeutic approaches (Dodick, 2018)

Mechanisms And Rationale: CGRP Antagonists And 5-HT1 Agonists

• CGRP antagonism:

• • CGRP is elevated during attacks; infusion triggers migraine in susceptible individuals (Edvinsson, 2019).
  • Blocking CGRP receptors or binding CGRP reduces meningeal vasodilation, mast cell degranulation, and nociceptive sensitization.
  • Clinical effect: fewer monthly migraine days, reduced acute medication use, improved function without vasoconstriction

• 5-HT1B/1D agonism (triptans):

• • Reduce presynaptic CGRP and glutamate release; cranial vasoconstriction helps abort pain.
  • High responder rates; limited by cardiovascular contraindications.

• 5-HT1F agonism (ditans, e.g., lasmiditan):

• • Inhibits trigeminal neurotransmission without vasoconstriction; useful in vascular disease; watch for CNS sedation.

Why combine?

• Acute gepant use alongside preventive mAb is mechanistically sound (ligand vs receptor blockade, different time scales) with supportive safety data.
• Triptan + NSAID (e.g., sumatriptan-naproxen) enhances sustained pain freedom via dual mechanisms.

References:

• CGRP neurobiology and clinical implications (Edvinsson, 2019)
• Migraine pathophysiology review (Charles, 2018)

Medication Interactions And Safety Considerations

Under Dr. Cardenas’ oversight, we carefully review:

• Cardiovascular risk with triptans; baseline blood pressure and cardiovascular assessment.
• Serotonergic load with SSRIs/SNRIs; educate on serotonin syndrome red flags (rare).
• CYP3A4 interactions with certain gepants; assess liver function in hepatic disease.
• Teratogenicity (valproate, topiramate precautions); pregnancy/lactation planning.
• Hypertension or constipation signals with erenumab; monitor and manage proactively.
• MOH thresholds; plan “drug holidays” or preventive up-titration to reduce acute reliance.

References:

• American Headache Society Position Statement (AHS, 2021)
• FDA labels for individual agents

Functional Medicine Foundations In Migraine

My functional medicine approach stabilizes neural excitability and reduces systemic drivers (Sun-Edelstein & Mauskop, 2009; Ramsden et al., 2021):

• Nutrition:

• • Emphasize whole-food, anti-inflammatory patterns; consistent meals to avoid glycemic dips.
  • Hydration tailored to body mass/activity; dehydration is a common precipitant.
  • Identify triggers: tyramine, nitrites, MSG, alcohol (especially red wine), excessive caffeine.
  • Magnesium (glycinate/citrate, 200–400 mg elemental/day), riboflavin (B2, 400 mg/day), and CoQ10 (100–300 mg/day) have preventive evidence; ensure vitamin D
  • Omega-3 fatty acids tilt toward pro-resolving mediators; optimize omega-6:omega-3 balance.

• Sleep:

• • Regular schedules; treat sleep apnea and bruxism; optimize sleep duration.
  • Blue light hygiene, room temperature control, and CBT-I

• Stress and autonomic regulation:

• • HRV biofeedback, paced breathing, mindfulness, graded exposure to triggers.
  • Moderate, consistent exercise reduces frequency; avoid overexertion spikes.

• Hormonal considerations:

• • Menstrual migraine: short-term mini-preventives (NSAIDs/triptans), lifestyle stabilization; collaborate with gynecology for contraceptive strategies.

• Gut-brain axis:

• • Address dyspepsia, reflux, IBS, and constipation that limit medication tolerance or elevate systemic inflammation.
  • Consider probiotics and fiber strategies for bowel regularity; especially relevant with constipating medications (e.g., erenumab).

Rationale: Stabilizing systemic inputs reduces hypothalamic triggers and immune-neurovascular reactivity, complementing pharmacologic and manual therapies.

References:

• Nutraceuticals and headache (Sun-Edelstein & Mauskop, 2009)
• Dietary fatty acids and headache (Ramsden et al., 2021)

Rehabilitation And Movement: Practical Protocols

I tailor exercise and rehab to each patient’s tolerance (Luedtke et al., 2012):

• Cervical and thoracic mobility:

• • Gentle segmental mobilizations, graded end-range isometrics, and thoracic extension drills counter desk postures.

• Scapular stabilization:

• • Low-load, high-frequency activation of middle/lower trapezius and serratus anterior to reduce neck loading.

• Sensorimotor retraining:

• • Deep neck flexor endurance; oculomotor and vestibular exercises for visual motion sensitivity or vestibular migraine phenotype.

• Breathing mechanics:

• • Diaphragmatic breathing improves vagal tone and reduces overuse of accessory neck muscles.

• Graded activity:

• • Accumulate moderate-intensity aerobic work weekly; avoid sudden intensity spikes that precipitate attacks.

Why it works:

• Reduces nociceptive input from pericranial tissues to the trigeminocervical complex.
• Improves autonomic balance and enhances endogenous pain inhibition.
• Boosts sleep and metabolic control, reducing susceptibility to triggers.

References:

• Exercise and physical therapy in migraine/TTH (Luedtke et al., 2012)

Personal Injury Context: Post-Traumatic Headache And Migraine

In personal injury and post-concussive settings, I often see:

• Post-traumatic headache with migrainous phenotype (photophobia/phonophobia, movement-aggravated pain, cognitive fog).
• Cervical strain/sprain maintaining trigeminocervical sensitization.
• Vestibular-ocular dysfunction and visual motion sensitivity.

Our integrated pathway:

• Medical evaluation by Dr. Cardenas to rule out intracranial injury, vascular compromise, and to manage pharmacotherapy.
• Early education, sleep stabilization, and activity below the symptom threshold.
• Cervical and vestibular rehab, oculomotor retraining, and graded return to work/sport.
• Consider gepants or triptans for acute attacks; preventive options if frequency persists beyond the acute window.

References:

• International Headache Society concussion guidelines; Silverberg & Iverson (2013)

Special Populations

• Children and adolescents:

• • Shorter duration criteria (2–72 hours).
  • Emphasize lifestyle consistency; ibuprofen/acetaminophen first-line; sumatriptan nasal or rizatriptan in age-appropriate patients; caution with preventives; CBT effective (Ashina et al., 2021).

• Pregnancy and lactation:

• • Prioritize non-pharmacologic measures; acetaminophen preferred; limited NSAID use (avoid 3rd trimester); avoid valproate/topiramate; neuromodulation and magnesium may help; consult obstetrics (ACOG guidance).

• Older adults:

• • New onset after 50 warrants imaging; evaluate for giant cell arteritis when suggestive; prefer non-vasoconstrictive agents; watch polypharmacy.

• Cardiovascular disease:

• • Avoid triptans; consider gepants or lasmiditan; manage risk factors aggressively.

References:

• AHS Consensus

Building A Patient-Centered Migraine Plan In Our Clinic

Our stepwise process:

1. Assessment and safety:

• • SNOOP red flags; neuro exam; identify phenotype (migraine with/without aura, vestibular, menstrual).
  • Review comorbidities and medications; consider imaging or labs when indicated.

• Education and expectations:

• • Explain migraine biology and phases; outline acute and preventive strategies; set measurable goals.

• Acute plan:

• • Early treatment strategy; choose best agent (triptan/gepant/ditan/NSAID), route, and antiemetic adjuncts.
  • Limit use to prevent MOH; document response.

• Preventive plan:

• • If indicated, select oral preventive or CGRP mAb/gepant; align with comorbidities and preferences.
  • Layer nutraceuticals (magnesium, riboflavin, CoQ10) when appropriate.

• Integrative manual and rehab care:

• • Cervical/thoracic manual therapy, trigger point strategies, graded exercise, sensorimotor retraining.

• Functional foundations:

• • Sleep schedule, hydration, nutrition, stress tools, light/noise management.

• Follow-up and iteration:

• • Reassess every 4–12 weeks; adjust doses, switch or add modalities; monitor HIT-6, MIDAS, and patient-reported outcomes.

• Long-term maintenance:

• • Taper preventive meds after sustained control; maintain exercise/sleep; empower self-management.

Collaboration With Dr. Maria Guadalupe Cardenas, MD

Dr. Cardenas’ role as Medical Director and Collaborative Physician ensures:

• Safe, evidence-based pharmacologic plans tailored to comorbidities and patient goals.
• Timely referrals for neurology, imaging, or procedures (e.g., onabotulinumtoxinA).
• Vigilant monitoring for adverse effects, interactions, and BP/lipid/metabolic control.
• Integration of internal medicine insights — thyroid function, anemia, vitamin D, sleep apnea — that materially influence migraine burden.

Our shared documentation and case reviews support continuity, risk mitigation, and superior outcomes.

Practical Case Patterns And Clinical Pearls

• The pressure-only migraine: Bilateral, pressure-like pain with photophobia and activity aggravation can still meet migraine criteria — avoid misclassifying as TTH if activity worsens pain.
• The neck-first prodrome: Neck stiffness a day before headache is common. Proactive soft-tissue care and early acute medication can shorten the attack.
• The late responder: Patients who miss the early window may benefit from gepants, intranasal formulations, or non-oral options; coach on timing.
• The overuse cycle: When acute meds exceed monthly thresholds, pivot to preventive therapy and structured drug holidays with bridging strategies.

Outcome Measurement And Quality Improvement

We track:

• Monthly migraine days and acute medication days
• HIT-6 and MIDAS scores
• Sleep hours and efficiency; hydration logs
• Exercise frequency/intensity
• Cervical ROM and deep neck flexor endurance
• HRV trends (where available)

These metrics enable individualized titration and shared decision-making.

An Integrative Neurobiological Narrative: From Synapse To Systems-Level Care

To appreciate why modern interventions work, we must zoom in on the synaptic level and then zoom out to the systems perspective that guides our integrative model.

The Neurological Ballet: Synaptic Transmission In Pain Pathways

Neurons communicate via synaptic transmission, where vesicles release neurotransmitters into the synaptic cleft. Vesicle docking relies on the SNARE complex—including SNAP-25—to fuse and release messengers such as CGRP and Substance P (Südhof, 2013). In trigeminovascular networks, these messengers propagate pain and neurogenic inflammation.

• CGRP: a potent vasodilator that sensitizes nerve fibers, activates mast cells, and amplifies nociception (Edvinsson et al., 2018).
• Substance P: contributes to pain transduction and neurogenic inflammation.

Chronic mechanical irritation — e.g., upper cervical dysfunction or myofascial hypertonicity — can sustain afferent barrage into the trigeminocervical complex, lowering thresholds for attack initiation. My clinical experience aligns with this mechanism: precise chiropractic adjustments, soft-tissue release, and postural correction reduce peripheral nociceptive drive, thereby downregulating central excitability over time (Biondi, 2005; Luedtke et al., 2012).

Botox As A Targeted Presynaptic Intervention

OnabotulinumtoxinA (Botox) cleaves SNAP-25, disrupting the SNARE complex and preventing vesicle fusion, thereby blocking the release of CGRP and Substance P from targeted sensory nerve terminals (Dodick et al., 2010). The PREEMPT protocol applies 31 injections across corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinals, and trapezius, reflecting both neuroanatomy and common myofascial generators in chronic migraine.

Clinical synergy: correcting cervical mechanics and myofascial dysfunction through chiropractic while Botox suppresses presynaptic neuropeptide release reduces dual drivers (structural and biochemical) of chronic migraine. For patients with refractory frequent migraine, I often see enhanced durability when these approaches are combined with sleep, nutrition, and stress stabilization.

The CGRP Revolution: Monoclonal Antibodies And Gepants

Deep mechanistic understanding of CGRP led to two major therapeutic strategies:

• Ligand binders (mAbs): fremanezumab, galcanezumab, eptinezumab bind CGRP, altering its conformation so it cannot activate its receptor.
• Receptor blockers: erenumab (mAb) and gepants (rimegepant, ubrogepant, atogepant, zavegepant) occupy the receptor and prevent CGRP binding.

These agents do not cause vasoconstriction, have long half-lives (for mAbs), minimal drug-drug interactions (protein catabolism rather than hepatic CYP metabolism for mAbs), and are effective in reducing monthly migraine days and acute medication use (Edvinsson, 2019; Urits et al., 2020).

Clinical safety updates since late 2025–2026 emphasize vigilance for new-onset or worsening hypertension and Raynaud’s phenomenon across the class. Biological plausibility is strong: blocking a potent vasodilator may tilt vasomotor tone toward vasoconstriction. My practice response: counsel patients, monitor blood pressure, and screen for digital color changes or pain in cold environments; consider comorbidity profiles when selecting specific agents.

Principles Of Migraine Pharmacotherapy: Acute And Preventive Strategy

I always create a clear, stratified plan:

• Acute plan (“put out the fire” ):

• • Treat early; select based on severity and contraindications.
  • Provide a rescue option if first-line fails (e.g., alternative class or non-oral route).
  • Coordinate with antiemetics and hydration; avoid exceeding MOH thresholds.

• Preventive plan “prevent the fire” ):

• • Initiate when frequency/disability warrants or acute therapy is limited.
  • Choose comorbidity-synergistic agents (e.g., beta-blocker for hypertension; SNRI for mood; topiramate for obesity).
  • Use CGRP mAbs/gepants when appropriate — now supported as first-line prevention by recent consensus statements — and counsel on 3–6 month commitment to assess efficacy.
  • Integrate sleep, nutrition, stress, and rehab — medication alone rarely addresses multifactorial drivers.

References:

• AHS Consensus Statement (Ailani, Burch, & Robbins, 2021)
• Comprehensive pharmacologic review (VanderPluym et al., 2021)

A Summary Of Migraine-Specific Treatment Targets

• Triptans: 5-HT1B/1D agonists; presynaptic CGRP inhibition and cranial vasoconstriction; best taken early.
• Gepants: CGRP receptor antagonists; postsynaptic blockade; useful in cardiovascular comorbidity or triptan intolerance; effective as acute and preventive.
• Ditans (lasmiditan): 5-HT1F agonist; presynaptic inhibition of CGRP without vasoconstriction; watch CNS sedation and post-dose driving restriction.
• OnabotulinumtoxinA (Botox): Presynaptic SNAP-25 cleavage; reduces neuropeptide release at targeted pericranial sensory terminals; used in chronic migraine.
• CGRP monoclonal antibodies:

• • Ligand binders (fremanezumab, galcanezumab, eptinezumab) — block CGRP in the synaptic cleft.
  • Receptor binder (erenumab) — occupies the receptor; watch constipation and BP.

The map underscores mechanism-based, personalized intervention.

The Critical Role Of Primary And Integrative Care

Approximately 70% of migraine patients are managed in primary care (Ashina et al., 2021). Our integrated model, joining internal medicine oversight and chiropractic/functional expertise, is designed to meet this need:

• We identify and manage migraine at the first point of contact.
• We provide safe, evidence-based, multidisciplinary care
• We emphasize education, shared decision-making, and long-term maintenance
• We continuously refine plans through outcome tracking and case reviews.

Extended Narrative: Deep Dive Into Physiological Underpinnings And Clinical Translation

To meet the depth our readers and clinical colleagues appreciate, I expand on key neurobiological and clinical concepts and show how they guide our protocols.

Hypothalamic Dysmodulation: The Migraine “Premonitory Engine”

Functional imaging reveals the hypothalamus as an early orchestrator of attack initiation (May, 2017). Dysmodulation affects circadian timing, appetite, thermoregulation, and autonomic tone, aligning with premonitory symptoms (yawning, cravings, mood shifts, neck stiffness). This supports early intervention — hydration, glycemic stabilization, gentle non-provocative manual therapy, and targeted acute pharmacology — before central sensitization consolidates.

• Why I act early: hypothalamic changes precede pain; CGRP release can be primed; descending inhibitory networks may be inefficient. Stopping peripheral input and stabilizing physiology can shift the trajectory away from full-blown attacks (Goadsby et al., 2017).

Trigeminovascular Activation: From Peripheral Sparks To Central Flames

The ophthalmic division (V1) of the trigeminal nerve innervates dura and cranial vessels, converging at the trigeminal nucleus caudalis. Activation yields CGRP, Substance P, and other mediators, driving vasodilation and mast cell degranulation. This creates a feedback loop of neurogenic inflammation and sensitization. Blocking CGRP or modulating serotonin here is fundamental (Edvinsson et al., 2018; Iyengar et al., 2019).

• Why chiropractic matters: upper cervical afferents (C1–C3) converge with trigeminal pathways. If cervical tissues send persistent nociceptive signals (joint restriction, trigger points, postural strain), thresholds for trigeminal activation decline. Precise adjustments, soft-tissue release, and posture retraining reduce the afferent barrage into shared nuclei, helping normalize central processing.

Central Sensitization: The Pain Amplifier

Repeated peripheral input drives plastic changes in dorsal horn and brainstem nuclei. Patients report cutaneous allodynia, diffuse hypersensitivity, and prolonged postdrome. Drug timing and manual care are sequenced to limit sensitization:

• Early triptan or gepant to blunt neuropeptide signaling and nociception.
• Non-provocative manual care during prodrome to avoid triggering a full attack.
• Consistent sleep and stress stabilization to improve descending inhibitory control.

Serotonin And CGRP: Balancing The Synapse

Triptans increase presynaptic 5-HT1B/1D signaling, reducing CGRP release and causing cranial vasoconstriction. Ditans (5-HT1F agonists) inhibit CGRP release without vasoconstriction, which is critical in cardiovascular disease. Gepants and CGRP mAbs block postsynaptic CGRP signaling with vaso-neutral profiles (Diener et al., 2015; Ailani et al., 2021).

• Why combination therapy: sumatriptan-naproxen combines serotonin-mediated anti-CGRP effects with COX inhibition, enhancing sustained freedom. Gepant + mAb leverages receptor/ligand blockade at different timescales, improving reliability without vasoconstriction.

OnabotulinumtoxinA: Presynaptic Shutoff For Chronic Migraine

By cleaving SNAP-25, Botox turns off vesicle fusion, reducing CGRP and Substance P release. Applying the PREEMPT injection map aligns with the most common pericranial generators, where sensory nerve endings in muscles and fascia drive nociceptive input (Dodick et al., 2010). For patients with chronic migraine, this can dramatically reduce monthly migraine days.

• Why I pair with rehab: muscle imbalance (upper trapezius/SCM dominance, inhibited lower trapezius/serratus) perpetuates cervical strain and nociceptive input. Correcting biomechanics reduces the need for ongoing neurotransmitter blockade over time and improves function.

Autonomic Regulation: Vagus, HRV, And Stress Physiology

Migraine involves a dysregulated autonomic balance. I use HRV biofeedback, paced breathing, and mindfulness to shift toward parasympathetic dominance. Devices like nVNS act on vagal pathways to dampen trigeminovascular excitability without drug interactions (Ailani et al., 2021).

• Why this matters: stress reduces descending inhibition, increases hypothalamic irritability, and worsens sleep. Improving autonomic balance raises thresholds for trigger reactivity.

Nutrition And Metabolic Stability: Foundations For Neural Resilience

Glycemic dips and dehydration are common triggers. I emphasize steady-state nourishment, hydration, and evidence-based nutraceuticals (magnesium, riboflavin, CoQ10). I assess omega-3 intake and inflammatory balance, coach trigger identification, and tailor plans to the patient’s context (Sun-Edelstein & Mauskop, 2009; Ramsden et al., 2021).

• Why I individualize: nutraceuticals are not one-size-fits-all. Magnesium can help with neuronal stability and sleep; riboflavin and CoQ10 support mitochondrial function relevant to neuronal energy in migraine physiology.

Vestibular And Oculomotor Rehabilitation: When Dizziness And Motion Sensitivity Dominate

Vestibular migraine and concussion-related dizziness respond to oculomotor and vestibular exercises (gaze stabilization, visual motion desensitization, balance progressions). Pairing these with cervical proprioception training integrates systems and reduces trigger sensitivity during visual overload.

• Why it works: aligning sensory inputs across vestibular, visual, and proprioceptive channels lowers central mismatch, which otherwise drives motion sensitivity and migraine exacerbation.

Case-Based Integration: How We Assemble The Plan

I integrate findings from history, exam, and patient-reported triggers into a cohesive plan. Here’s how the pieces fit:

• Phenotype and timing:

• • If attacks start with neck tightness and visual sensitivity, I anticipate hypothalamic prodrome and cervicogenic input, and act early with hydration, magnesium, gentle manual therapy, and an acute agent.
  • If the patient often misses the early window, I choose agents effective later (e.g., gepants, intranasal zavegepant, or subcutaneous sumatriptan) and coach symptom tracking for earlier intervention.

• Comorbidities:

• • Hypertension: prefer candesartan or beta-blockers; watch erenumab’s BP
  • Depression/anxiety: consider SNRIs or TCAs, but balance anticholinergic side effects; pair with HRV training.
  • Obesity: topiramate if acceptable; counsel on cognitive side effects.
  • IBS-C: avoid erenumab due to constipation risk; prefer ligand mAbs or gepants.

• Functional and rehab layers:

• • Posture correction, thoracic mobility, scapular activation, and deep neck flexor endurance.
  • Sleep optimization and trigger management anchored in daily routines.
  • Stress modulation with paced breathing and mindfulness; consider nVNS in selected patients.

• Tracking and iteration:

• • I set measurable targets: reduce monthly migraine days, improve HIT-6/MIDAS scores, normalize sleep patterns, lower acute medication days, increase deep neck flexor endurance and thoracic mobility.
  • Regular check-ins every 4–12 weeks to titrate therapy.

Practical Guidance For Clinicians And Patients

• Think migraine first with movement-aggravated head pain and sensory sensitivities — even when pain is bilateral or pressure-like.
• Screen quickly with ID Migraine; rule out secondary causes using SNOOP.
• Treat early; select agents that match phenotype and comorbidities.
• Limit acute meds to avoid MOH; incorporate preventive therapy when indicated.
• Use CGRP-targeted therapies and ditans for safer vascular profiles.
• Integrate chiropractic care, medical oversight, functional medicine, and rehabilitation for durable results.
• Track outcomes, adjust regularly, maintain long-term health foundations.

Acknowledging Clinical Observations And Professional Discourse

I incorporate insights I’ve shared publicly and observed clinically — from Chiropracticscientist.com and my LinkedIn practice narratives — including the role of upper cervical segmental dysfunction, thoracic mechanics, trigger points, screen-driven postural strain, and how coordinated manual care with internal medicine oversight enhances safety, treatment timing, and overall outcomes.

Final Takeaways

• Migraine is a brain disorder with systemic signatures; understanding hypothalamic, trigeminovascular, and sensitization dynamics clarifies treatment timing and choice.
• Evidence-based pharmacology and mechanism-driven devices are most effective when integrated with manual therapy, rehab, sleep, nutrition, and stress.
• Multidisciplinary care — internal medicine direction with chiropractic-led neuromusculoskeletal and functional strategies — delivers safer, faster, more complete recoveries.
• Outcome tracking drives precision, empowers patients, and guides long-term maintenance.

I invite patients and providers to connect with our team at Injury Medical Clinic PA in El Paso. With Dr. Maria Guadalupe Cardenas, M.D.M., guiding medical decisions and our integrated chiropractic and functional approach, we offer a comprehensive path forward for those living with migraine.

References

• AHS consensus statement: Update on integrating new migraine treatments into clinical practice (Ailani, J., Burch, R. C., & Robbins, M. S., 2021). Headache: The Journal of Head and Face Pain.
• Migraine: epidemiology and systems of care (Ashina, M., Hansen, J. M., Do, T. P., & Olesen, J., 2021). Nature Reviews Neurology.
• The pathophysiology of migraine: Implications for clinical management (Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S., 2017). New England Journal of Medicine.
• Migraine (Charles, A., 2018). New England Journal of Medicine.
• CGRP and migraine: Neurobiology and clinical implications (Edvinsson, L., 2019). Nature Reviews Neurology.
• The International Classification of Headache Disorders, 3rd edition (IHS, 2018). International Headache Society.
• Validation of a brief migraine screener (ID Migraine) (Lipton, R. B., Dodick, D., Sadovsky, R., et al., 2003). JAMA.
• Premonitory symptoms in migraine (Giffin, N. J., Ruggiero, L., Lipton, R. B., Silberstein, S. D., et al., 2003). Neurology.
• Manual therapies for headache (Biondi, D., 2005). Headache: The Journal of Head and Face Pain.
• Exercise and physical therapy in migraine and tension-type headache (Luedtke, K., May, A., & Jürgens, T. P., 2012). Manual Therapy.
• Dietary fatty acids and headache (Ramsden, C. E., Zamora, D., Horowitz, M. S., et al., 2021). BMJ.
• OnabotulinumtoxinA for chronic migraine: PREEMPT pooled results (Dodick, D. W., Turkel, C. C., DeGryse, R. E., et al., 2010). Headache: The Journal of Head and Face Pain.
• New therapeutic approaches for prevention and treatment of migraine (Diener, H. C., Charles, A., Goadsby, P. J., & Holle, D., 2015). The Lancet Neurology.
• Neurotransmitter release: the last millisecond in the life of a synaptic vesicle (Südhof, T. C., 2013). Neuron.
• Comprehensive review of pharmacologic agents for migraine (VanderPluym, J. H., Halker Singh, R. B., Urits, I., et al., 2021). Pain and Therapy.
• Global burden of headache (Steiner, T. J., Stovner, L. J., Jensen, R., et al., 2018). The Journal of Headache and Pain.
• Migraine and the trigeminovascular system — 40 years and counting (Ashina, M., Buse, D. C., Ashina, H., et al., 2019). The Lancet Neurology.
• CGRP and the trigeminal system: mechanisms and role in migraine (Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N., 2018). Cephalalgia.
• Migraine: Multiple processes, complex pathophysiology (Burstein, R., Noseda, R., & Borsook, D., 2015). The Journal of Neuroscience.
• The migraine matrix: A new framework for understanding migraine (May, A., 2017). Neurology.
• Evidence-based review of fremanezumab for migraine (Urits, I., Clark, G., An, D., et al., 2020). Pain and Therapy.
• Nutraceuticals in headache management (Sun-Edelstein, C., & Mauskop, A., 2009). Headache.
• FDA drug labels and safety communications (various agents).

SEO tags: migraine diagnosis, migraine treatment, CGRP antagonists, triptans, ditans, gepants, neuromodulation devices, integrative chiropractic, functional medicine for migraine, internal medicine collaboration, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso Texas, hypothalamus migraine, trigeminovascular system, vestibular migraine, menstrual migraine, personal injury headache, rehabilitation for migraine, cervical dysfunction and migraine, photophobia, phonophobia, ID Migraine screener, SNOOP red flags, Botox chronic migraine, SNAP-25, PREEMPT protocol, ergonomics and migraine, HRV biofeedback, magnesium riboflavin CoQ10, omega-3 fatty acids, sleep hygiene migraine, post-concussion headache, vestibular rehab migraine, autonomic dysfunction migraine, medication overuse headache prevention